Measurable residual disease and maintenance therapy in acute myeloid leukemia (AML), stemness and chemotherapy resistance in AML, and effects of babesiosis on red blood cells in sickle cell disease

In this week's episode, we’ll learn more about how measurable residual disease might help guide decisions about post-transplant gilteritinib maintenance in FLT3-ITD acute myeloid leukemia, or AML; how stemness contributes to chemotherapy resistance in AML; and effects of babesiosis on red blood cells from individuals with sickle cell disease, sickle cell trait, and wild-type hemoglobin.

Subscribe today via iTunes   Google Play    Spotify to receive notification of each new episode as it's published.

 

The articles highlighted in this episode are listed below:

• Measurable residual disease and posttransplantation gilteritinib maintenance for patients with FLT3-ITD–mutated AML
• GATA2 links stemness to chemotherapy resistance in acute myeloid leukemia
• Babesiosis and sickle red blood cells: loss of deformability, altered osmotic fragility, and hypervesiculation